Singapore, Mar 02, 2010: Waters has introduced the first UltraPerformance LC (UPLC) analytical size-exclusion chromatography (SEC) solution for the characterization of proteins and their aggregates.

The UPLC solution combines the first commercial sub two micron particle for SEC applications “ the new patent pending ACQUITY UPLC BEH200, 1.7 SEC Columns - with the Waters ACQUITY UPLC System to give manufacturers the ability to separate and quantify monoclonal antibodies (mAb) and their aggregates in less than four minutes, faster than with conventional liquid chromatography, and still meet FDA requirements.

Since the launch of ACQUITY, our biopharmaceutical customers have asked us to bring the benefits of UPLC performance to size-exclusion chromatography said Dr. Dorothy Phillips, Director of Chemistry Operations Strategic Marketing, Waters Division. Overcoming this incredible challenge was only possible after much innovation and invention. Our new solution allows customers to monitor monoclonal antibody aggregation at speeds up to 10 times faster at comparable or better resolution than before, helping them overcome their challenges of developing novel biotherapeutics in less time and at lower costs.